Neurocrine Biosciences Reports INGREZZA Achieves Higher VMAT2 Occupancy Than AUSTEDO XR in Head-to-Head Study

Neurocrine Biosciences Inc. has reported the first head-to-head study comparing VMAT2 occupancy between INGREZZA and AUSTEDO XR. Using PET imaging, the study found that INGREZZA achieved higher VMAT2 occupancy at therapeutic doses (83% for 40 mg and 92% for 80 mg) compared to AUSTEDO XR (54% for 24 mg and 70% for 48 mg). These results are significant for treating involuntary movement disorders such as tardive dyskinesia and Huntington’s disease chorea. The findings were presented at a recent meeting.